<DOC>
	<DOCNO>NCT00004047</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness DX-8951f treating patient hematologic cancer .</brief_summary>
	<brief_title>Chemotherapy Treating Patients Who Have Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose DX-8951f patient advance myelodysplastic syndrome , refractory acute myeloid lymphocytic leukemia , refractory transform chronic lymphocytic leukemia , chronic myelogenous leukemia blastic phase . II . Evaluate quantitative qualitative toxic effect regimen determine duration reversibility effect patient . III . Make preliminary determination antileukemic activity regimen patient . IV . Evaluate pharmacokinetics regimen patient . OUTLINE : This dose escalation study . Patients receive DX-8951f IV 30 minute daily 5 day . Treatment continue every 3 week least 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos DX-8951f maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose limit toxicity . Patients follow every 3 month death . PROJECTED ACCRUAL : Approximately 20-25 evaluable patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Exatecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow hematologic malignancy : Advanced myelodysplastic syndrome Refractory anemia excess blast Refractory anemia excess blast transformation Chronic myelomonocytic leukemia Refractory acute myeloid leukemia ( AML ) First salvage primary refractory AML first complete response ( CR ) great 12 month duration least second salvage therapy Once maximum tolerate dose determine , intermediate AML prognosis ( first CR duration great 12 month le 24 month ) eligible Refractory acute lymphocytic leukemia Refractory transform chronic lymphocytic leukemia Chronic myelogenous leukemia blastic phase No CNS disease PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : No specified Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 2.0 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No active congestive heart failure No uncontrolled angina No myocardial infarction within past 6 month Other : Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test No concurrent grade 4 infection No psychiatric disorder mental disability No life threaten illness PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : At least 30 day since prior cytotoxic therapy recover No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy great 25 % skeleton Surgery : No concurrent surgery Other : At least 3 week since prior investigational drug ( include analgesic antiemetic ) Recovered toxic effect prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>